...
首页> 外文期刊>American Journal of Cancer Research >Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters
【24h】

Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters

机译:新型粘液溶解剂对假性粘液性腹膜粘蛋白的疗效,可通过腹膜导管进行治疗

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Compared to current treatment for pseudomyxoma peritonei (PMP), the extraction of solubilised mucin through peritoneal catheter can be minimally invasive. However, mucin has variable appearance that may influence mucolysis. Hence, we investigated the mucolysis of 36 mucin samples with a novel agent. Using visual inspection and hardness index, PMP mucin was classified into three grades. The mucin pathological category was identified from patient record. Subsequently, the dissolution of the samples was tested. For in vitro, 1 g of mucin was treated to the mucolytic agent in 10 ml TRIS buffer at 37 deg. Celsius for 3 hours, with weighing of residual mucin. Control treatment was similar but received TRIS buffer. For in vivo, 2 g of implanted intra-peritoneal mucin in nude rats was treated to mucolytic (2 X 500 ul/24 hr, over 48 hours, plus another treatment before sacrifice at 56 hours, with weighing of residual mucin. Controls were treated but only with TRIS buffer. Six animals were used for each mucin grade (3 mucolytic treated & and 3 controls). Grades of mucin were soft mucin (62%), semi hard (20%) and hard mucin (18%). Diffuse peritoneal adenomucinosis had 50% of soft mucin and peritoneal mucinous carcinoma had 11% (emP = 0.0382/em). In vitro and in vivo absolute disintegration was 100% for soft, 57.38% and 48.67% for semi hard, 50% and 28.67% for hard mucin. Majority of mucin were soft with complete disintegration, the rest showed variable disintegration, suggesting that the mucolytic has potential for treating PMP.
机译:与目前的腹膜假粘液瘤(PMP)治疗相比,通过腹膜导管提取可溶性粘蛋白的侵袭性最低。但是,粘蛋白的外观可变,可能会影响粘液溶解。因此,我们研究了一种新型药物对36种粘蛋白样品的粘液溶解作用。通过目测和硬度指数,将PMP粘蛋白分为三个等级。从患者记录中鉴定出粘蛋白病理学类别。随后,测试样品的溶解度。对于体外,在37℃下在10ml TRIS缓冲液中将1g粘蛋白处理成粘液溶解剂。摄氏3小时,称重残留的粘蛋白。对照处理相似,但是接受了TRIS缓冲液。对于体内,将裸鼠中植入的2 g腹膜内粘蛋白进行粘液溶解(2 X 500 ul / 24 hr,历时48小时,再加上另一种处理,然后在56小时处死,称重残留的粘蛋白)。但仅使用TRIS缓冲液。每种粘蛋白等级均使用6只动物(3种经粘液溶解处理的动物和3个对照),粘蛋白等级为软粘蛋白(62%),半硬粘蛋白(20%)和硬粘蛋白(18%)。 )弥漫性腹膜腺粘液病有50%的软黏蛋白,腹膜粘液癌有11%( P = 0.0382 )。体内和体外的软分解绝对崩解分别为100%,57.38%和48.67%。半粘质,硬质粘蛋白为50%,28.67%,大多数粘蛋白为软质,完全崩解,其余呈可变性崩解,表明粘液溶解剂具有治疗PMP的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号